Related Experiment Video
Updated: Aug 7, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
Abdulaziz Alolayan1, Abdullah S Aldamegh2, Azzah Alkhayrat1
1Pharmacy Department, Prince Sultan Military Medical City, Saudi Arabia.
Insights
Anakinra, an IL-1 receptor antagonist, offers a potential lifesaving treatment for children with critical COVID-19 and multisystem inflammatory syndrome (MIS-C). This case study highlights successful intravenous anakinra therapy in managing cytokine storm complications.
Area of Science:
- Pediatric critical care medicine
- Infectious diseases
- Immunology
Background:
- Coronavirus disease (COVID-19) is a global pandemic with significant mortality.
- Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of COVID-19, often involving a cytokine storm.
- Anakinra, an interleukin-1 (IL-1) receptor antagonist, is used to mitigate exaggerated inflammatory responses.
Abstract:
Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress the exaggerated inflammatory response in such conditions, and it is potentially lifesaving in a cytokine storm. We present the case of a patient with critical COVID-19 associated with multisystem inflammatory syndrome in children (MIS-C) successfully treated with anakinra intravenous (IV) infusion.
Related Concept Videos
Continuous Renal Replacement Therapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

